Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 9/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.44 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14459896 | 0.79 | SLC6A4 (0.72) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL2632639 | 0.79 | SLC6A4 (0.72) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL2625050 | 0.79 | KCNA5 (0.62) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL942130 | 0.79 | SLC6A4 (0.72) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL2624927 | 0.79 | KCNA5 (0.62) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL2624897 | 0.79 | SLC6A4 (0.72) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Hydrochloric Acid SCHEMBL941452 | 0.79 | KCNA5 (0.72) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL13198873 | 0.79 | SLC6A4 (0.62) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Hydrochloric Acid SCHEMBL1419021 | 0.79 | KCNA5 (0.72) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Hydrochloric Acid SCHEMBL1016965 | 0.79 | KCNA5 (0.72) | SLC6A4KCNA5SCN5AKCND2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188140-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. | 2012-05-29 | — | — | US | disclosed |
| US-8188140-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. | 2012-05-29 | — | — | US | disclosed |
| US-20110118329-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110118329-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118329-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | KCNN1, KCNN2, KCNN3 | SLC6A4 296/4885KCNA5 48/4885SCN5A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.